Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Douglas Pharmaceuticals Limited

https://douglas.co.nz/

Latest From Douglas Pharmaceuticals Limited

US FDA Asks Manufacturers To Fix Disruption In Isotretinoin REMS

The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.

Risk Management Drug Safety

Pfizer sells Icagen drug discovery, not compounds

Four years after Pfizer acquired Icagen for $56m, the big pharma sold the drug discovery firm to XRpro Sciences for up to $11m, which would seem to be a big discount if the deal gave the buyer access to compounds generated by Icagen's ion channel biology platform.

Neurology Respiratory

FDA guides on abuse-deterrent opioids; generics direction pending

The FDA on 1 April unveiled its final guidance advising makers of brand-name opioids about what they need to do to obtain abuse-deterrent language in the labeling of their products.

Neurology

INTERVIEW: Actavis CEO Saunders staying put as Allergan deal nears close

Actavis CEO Brent Saunders has been the head of three different companies in less than two years, but with the $66bn acquisition of Allergan about to close any day now, he told Scrip that he's found the place where he plans to retire.

Neurology
See All

Company Information

  • Industry
  • Biotechnology
UsernamePublicRestriction

Register